Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15246

    +

    P3.01-037 - Impact of Endobronchial Stents on Patients with NSCLC and Central Airway Obstruction (CAO) (ID 819)

    09:30 - 09:30  |  Author(s): M. Shehata
    • Abstract

    Background:
    Approximately 30% of lung cancer patients develop central airway obstruction (CAO) increasing the risk of post-obstructive pneumonia and respiratory failure. Therapeutic interventional bronchoscopy including airway stenting (AS) can provide immediate and effective palliation to improve patient quality of life (QoL). Unfortunately, there is little data about the impact on OS or the risk of hospitalization in patients with CAO mandating stent placement versus patients with CAO lesions that did not require stent placement.
    
    Methods:
    Between 2011-2014, twenty five patients with advanced lung cancer were evaluated by the Interventional Pulmonary (IP) Service at the University of Cincinnati for endobronchial stent placement for CAO. We retrospectively reviewed the OS and the risk of hospitalization in patients with lung cancer with CAO mandating stent placements versus patients who did not have lesions requiring stent placement. Death was considered as the endpoint. Kaplan-Meier method was used to calculate median overall survival and 95% CI. Cox model was used to test the overall survival difference between the patients who need stent and patients who do not need stent adjusted for age and sex. Logistic regression was used to test the hospitalization rate difference between the patients who need stent and patients who do not need stent adjusted for age and sex. Data were analyzed using the SAS ® Version 9.4.
    
    Results:
    Between 2011-2014, twenty five patients with advanced lung cancer were evaluated by the Interventional Pulmonary (IP) Service at the University of Cincinnati for endobronchial stent placement for CAO. Eight patients did not require placement of a stent and 17 patients had obstructive lesions that required stenting. Age and gender did not have any impact on the risk of hospitalization or OS of both of these groups of patients. The eight patients whose lesions did not mandate stent placement had a significantly lower risk of hospitalization compared to the 17 patients with CAO requiring a stent (OR 15.9, 95%CI 1.2, 209.1; p =0.035). Patients with advanced NSCLC and CAO that required IP stent placement had a median OS of 424 days (95%CI, 119-606 days) compared to a median OS of 729 days (95%CI, 426-. days) for patients with CAO not requiring a stent. Even with a lower survival in patients with stent placement, their OS of 424 days was slightly longer than the reported one-year survival for patients with stage IV NSCLC suggestive of improved outcome of patients with advanced stage NSCLC supported by IP.
    
    Conclusion:
    Lung cancer patients with less severe CAO have a lower risk of hospitalization and have better OS compared to patients with CAO mandating stent placement; however, CAO patients with IP evaluation and management in addition, may have improved OS suggesting that IP consultation may offer both improvements in QoL and OS to patients with advanced NSCLC and CAO.